Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial

Joanna M. Zakrzewska, Simon Tate, Dominique Derjean et al.|The Lancet Neurology|2017

Cited by 201